1/6
09:00 am
ydes
YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development
High
Report
YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development
1/5
09:00 am
ydes
YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap
Medium
Report
YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap
12/30
04:16 pm
ydes
True Velocity, Inc./DE (NASDAQ:YDES) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
True Velocity, Inc./DE (NASDAQ:YDES) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
12/24
04:16 am
ydes
True Velocity, Inc./DE (NASDAQ:YDES) is now covered by analysts at
Weiss Ratings. They set a "sell (d+)" rating on the stock.
Medium
Report
True Velocity, Inc./DE (NASDAQ:YDES) is now covered by analysts at
Weiss Ratings. They set a "sell (d+)" rating on the stock.
12/16
09:00 am
ydes
YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center
Low
Report
YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center
12/9
09:00 am
ydes
YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN
High
Report
YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN
12/2
09:00 am
ydes
YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection
High
Report
YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection
11/24
09:00 am
ydes
YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics
Medium
Report
YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics
11/5
08:30 am
ydes
YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA-Methylation Blood Test for Post-Treatment Breast Cancer Monitoring
Medium
Report
YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA-Methylation Blood Test for Post-Treatment Breast Cancer Monitoring